BnR Summit 2026

Belt & Road Summit - Deal-Making 2026

9 – 15 Sept 2026 | Hong Kong, China (Hong Kong)

ProjectUpdated on 14 August 2026

人源胰岛类器官治疗糖尿病的研发及产业化

生物医药早期项目孵化 at 周易生物

China (Hong Kong)

About

Nordia targets on the diabetes with personal or universal islet organoids generated from stem cells through its spontaneous formation of 3D structure of islets. Gene editing and T cell co-culture were used to reduce the immunogenicity. The islet organoids will be transplanted into the patients with biomaterial scaffolds for long-term control of blood glucose levels by steady insulin secretion. Nordia also offers islet-based research services such as drug/target screening.

Project Location

  • China (Hong Kong)

Project Website

http://nordiabio.com/

Project Format

  • Private Project

Go Global Project

  • Yes

ESG (Environmental, Social, and Governance)

  • Yes

Project Stage

  • Feasibility Study Completed

Main Project Sector

  • Technology

Technology

  • Bio-Tech
  • Health Technology
  • Medical Technology

Urban Development

  • Health Facilities
  • Technology Park

Total Project Value

  • 2,500,001 to 5,000,000 USD

Investment Capital Required

  • 5,000,001 to 7,500,000 USD

Interested Format of Cooperation

  • Direct Equity Investment
  • EPC / Turnkey
  • Requisition of Service
  • Open for Negotiation

Preferred Financing Model

  • Equity
  • Open for negotiation

Type(s) of Last Financing Round of the project (if Applicable)

  • Venture Capital (VC)

Main Service(s) Required

  • Professional Services

Similar opportunities